The clinical research affiliate of the Lupus Research Alliance, Lupus Therapeutics, announced a partnership with the biopharmaceutical company Nkarta, Inc. in developing the engineered natural killer (NK) cell therapy NKX019 as a potential treatment for people with refractory lupus nephritis who have not responded to standard treatment.
The full press release is available on the Lupus Therapeutics website.
Tags: lupus therapeutics, Nkarta, NKX019, NKTX